"Designing Growth Strategies is in our DNA"

U.S. Atrial Fibrillation Market Size, Share & Industry Analysis, By Drug Class (Anticoagulants and Anti-arrhythmic Drugs), By Route of Administration (Oral, Intravenous, and Others), By Distribution Channel (Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies), and Country Forecast, 2024-2032

Last Updated: February 17, 2025 | Format: PDF | Report ID: FBI109962

 

  1. Introduction
    1. Research Scope
    2. Market Segmentation
    3. Research Methodology
    4. Definitions and Assumptions
  2. Executive Summary
  3. Market Dynamics
    1. Market Drivers
    2. Market Restraints
    3. Market Opportunities
    4. Market Trends
  4. Key Insights
    1. Pipeline Analysis, By Key Players
    2. Impact of COVID-19 on U.S. Atrial Fibrillation Market
    3. Prevalence/Incidence of Atrial Fibrillation, U.S., 2023/2023
    4. New Product Launches
    5. Key Industry Developments - Mergers, Acquisitions and Partnerships
  5. U.S. Atrial Fibrillation Market Analysis, Insights and Forecast, 2019-2032
    1. Market Analysis, Insights and Forecast – By Drug Class
      1. Anticoagulants
      2. Anti-arrhythmic Drugs
    2. Market Analysis, Insights and Forecast – By Route of Administration
      1. Oral
      2. Intravenous
      3. Others
    3. Market Analysis, Insights and Forecast – By Distribution Channel
      1. Hospital Pharmacies
      2. Retail Pharmacies
      3. Online Pharmacies
  6. Competitive Analysis
    1. U.S. Market Share Analysis (2023)
    2. Company Profiles
      1. Johnson & Johnson Services, Inc.
        1. Overview
        2. Products
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. Financials (Based on Availability)
      2. Pfizer Inc.
        1. Overview
        2. Products
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. Financials (Based on Availability)
      3. Bayer AG
        1. Overview
        2. Products
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. Financials (Based on Availability)
      4. Bristol-Myers Squibb Company
        1. Overview
        2. Products
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. Financials (Based on Availability)
      5. Par Pharmaceutical
        1. Overview
        2. Products
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. Financials (Based on Availability)
      6. Sanofi
        1. Overview
        2. Products
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. Financials (Based on Availability)
      7. DAIICHI SANKYO COMPANY, LIMITED
        1. Overview
        2. Products
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. Financials (Based on Availability)
      8. Boehringer Ingelheim International GmbH
        1. Overview
        2. Products
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. Financials (Based on Availability)
Read Less

Figure 1: U.S. Atrial Fibrillation Market Revenue Breakdown (USD Billion, %) by Drug Class, 2023 & 2032

Figure 2: U.S. Atrial Fibrillation Market Value Share (%), by Drug Type, 2023 & 2032

Figure 3: U.S. Atrial Fibrillation Market Value Share (%), by Route of Administration, 2023 & 2032

Figure 4: U.S. Atrial Fibrillation Market Value Share (%), by Distribution Channel, 2023 & 2032

Figure 5: U.S. Atrial Fibrillation Market Share (%), By Company, 2023

Table 1: U.S. Atrial Fibrillation Market Revenue (USD Billion) Forecast, by Drug Class, 2019–2032

Table 2: U.S. Atrial Fibrillation Market Revenue (USD Billion) Forecast, by Route of Administration, 2019–2032

Table 3: U.S. Atrial Fibrillation Market Revenue (USD Billion) Forecast, by Distribution Channel, 2019–2032

  • 2019-2032
  • 2023
  • 2019-2022
  • 60
Consulting Services
    How will you benefit from our consulting services ?